Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data

Vivian P. Bykerk, Peter Nash, David Nicholls, Yoshiya Tanaka, Kevin Winthrop, Christina Popova, Nicola Tilt, Derek Haaland

Research output: Contribution to journalArticlepeer-review


Introduction: There is a paucity of data on how patient characteristics may affect the long-term durability of certolizumab pegol (CZP) in patients with rheumatoid arthritis (RA). This study therefore aimed to investigate CZP durability and reasons for discontinuation over 5 years between different subgroups of patients with RA. Methods: Data were pooled from 27 clinical trials in RA patients. Durability was defined as the percentage of patients randomized to CZP at baseline who were still on CZP treatment at a given timepoint. Post hoc analyses of clinical trial data on CZP durability and reasons for discontinuation among different patient subgroups were conducted using Kaplan–Meier curves and Cox proportional hazards modeling. Patient subgroups included: age (18– < 45/45– < 65/ ≥ 65 years), gender (male/female), prior tumor necrosis factor inhibitor (TNFi) use (yes/no), and disease duration (< 1/1– < 5/5– < 10/ ≥ 10 years). Results: Among 6927 patients, the durability of CZP was 39.7% at 5 years. Patients aged ≥ 65 years had a 33% greater risk of CZP discontinuation than patients 18– < 45 years (hazard ratio [95% confidence interval]: 1.33 [1.19–1.49]) and patients with prior TNFi use had a 24% greater risk of discontinuing CZP than patients without (1.24 [1.12–1.37]). Conversely, greater durability was observed among patients who had a baseline disease duration of ≥ 1 year. Durability did not differ in the gender subgroup. Of the 6927 patients, the most common reason for discontinuation was inadequate levels of efficacy (13.5%); followed by adverse events (11.9%); consent withdrawn (6.7%); lost to follow-up (1.8%); protocol violation (1.7%); other reasons (9.3%). Conclusions: CZP durability was comparable with durability data on other bDMARDs in RA patients. Patient characteristics that were associated with greater durability included younger age, TNFi-naïvety, and disease duration ≥ 1 year. Findings may be helpful in informing clinicians on a patient’s likelihood of discontinuing CZP, based on their baseline characteristics.

Original languageEnglish (US)
JournalRheumatology and Therapy
StateAccepted/In press - 2023


  • Certolizumab pegol
  • Durability
  • Rheumatoid arthritis
  • Tumor necrosis factor inhibitors

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy


Dive into the research topics of 'Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data'. Together they form a unique fingerprint.

Cite this